Skip to main content
Dryad

Data from: STAT3 sustains tumorigenicity following mutant KRAS ablation

Abstract

Mechanisms underpinning the residual tumorigenicity of mutant KRAS cancers following KRAS inactivation remain to be completely understood. Our studies show that KRAS ablation in pancreatic ductal adenocarcinoma (PDAC) prevents tumor growth contingent on the concomitant inactivation of the transcription factor STAT3. Mechanistically, the incurred losses of KRAS and STAT3 disrupt a temporal balance between tumor cell differentiation, proliferation, and self-renewal. Our findings identify a specific role for STAT3 in supporting cancer cell fitness with a particular focus on KRAS-inhibited tumors and provide a rationale for developing therapies targeting both mutant KRAS and STAT3. RNA sequencing data are presented for PDAC cells following CRISPR-mediated STAT3 and KRAS double knockouts compared to single knockouts, and with double knockouts following enhanced expression of the FOXA1 and FOXA2 genes. Chromatin immunoprecipitation analyses are presented with antibodies to phosphorylated STAT3 in parental and KRAS knockout cells and control antibodies in parental cells. Excel files of sequencing results prepared by Novogene Corp. are provided. In addition, Excel files are included for single-cell RNA-seq analyses of tumors formed by doxycycline-induced mutant KRAS (iKRAS) pancreatic cells and derived STAT3 knockout cells in mice treated with doxycycline and following removal of doxycycline for 4 days. The data was acquired by Cold Spring Harbor Laboratory Genome Center from the Loupe browser software.